Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TEVA | PRESS-RELEASE | neutral | 4/10 | Teva presented real-world survey data at a medical congress showing that AUSTEDO/AUSTEDO XR treatment for Huntington's d | Jun 5, 2026 |
| EDSA | PRESS-RELEASE | bullish | 6/10 | Edesa Biotech reported favorable exploratory data for paridiprubart in acute kidney injury (AKI) patients with respirato | Jun 5, 2026 |
| NRXP | PRESS-RELEASE | bullish | 7/10 | NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ket | Jun 5, 2026 |
| TSHA | PRESS-RELEASE | neutral | 2/10 | Taysha Gene Therapies granted 714,700 RSUs and an option for 468,600 shares to four new employees under its 2023 Inducem | Jun 5, 2026 |
| CMND | PRESS-RELEASE | neutral | 2/10 | Clearmind Medicine announced a live webinar on June 10, 2026, featuring investigators from Yale and Johns Hopkins to dis | Jun 5, 2026 |
| MCRB | PRESS-RELEASE | neutral | 5/10 | Seres Therapeutics announced a $25M buyout of future VOWST milestones from Nestlé Health Science and a lease restructuri | Jun 5, 2026 |
| NRXP | PRESS-RELEASE | bearish | 6/10 | NRx Pharmaceuticals closed an underwritten public offering of common stock at $3.50 per share, raising approximately $22 | Jun 4, 2026 |
| BGMS | PRESS-RELEASE | neutral | 5/10 | BGMS announced an all-stock business combination with Future NRG Sdn. Bhd., a Malaysia-based medical waste treatment com | Jun 4, 2026 |
| LYEL | PRESS-RELEASE | neutral | 3/10 | Lyell Immunopharma announced upcoming presentations of ronde-cel Phase 1/2 safety and translational data at the EHA 2026 | Jun 4, 2026 |
| SNDX | PRESS-RELEASE | neutral | 2/10 | Syndax Pharmaceuticals granted inducement awards for 66,700 shares to four new employees under the 2023 Inducement Plan. | Jun 4, 2026 |
| SCLX | PRESS-RELEASE | neutral | 4/10 | Scilex announced a June 15, 2026 payment date for its previously declared dividend of Semnur Pharmaceuticals (OTC: SMNR) | Jun 4, 2026 |
| TOMZ | PRESS-RELEASE | bullish | 5/10 | TOMI Environmental Solutions announced a signed purchase order for a custom SteraMist Hybrid system from a food producer | Jun 4, 2026 |
| EBS | PRESS-RELEASE | neutral | 2/10 | Emergent BioSolutions issued a press release announcing its partnership with Victoria's Voice Foundation for National Na | Jun 4, 2026 |
| LNZA | PRESS-RELEASE | bullish | 6/10 | LanzaTech's joint venture, Beijing Shougang LanzaTech Technology Co., Ltd., completed its IPO on the Hong Kong Stock Exc | Jun 4, 2026 |
| SPRC | PRESS-RELEASE | neutral | 4/10 | SciSparc's majority-owned subsidiary NeuroThera closed its acquisition of a ~54% interest in CliniQuantum for ~CAD$9.5M | Jun 4, 2026 |
| RZLT | PRESS-RELEASE | neutral | 3/10 | Rezolute announced four presentations at the ENDO 2026 conference, including an oral presentation of previously reported | Jun 4, 2026 |
| OCUL | PRESS-RELEASE | bullish | 7/10 | Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple dat | Jun 4, 2026 |
| AXSM | PRESS-RELEASE | neutral | 3/10 | Axsome Therapeutics announced presentations of new SYMBRAVO® data at the AHS 68th Annual Scientific Meeting, including p | Jun 4, 2026 |
| ALVO | PRESS-RELEASE | bullish | 7/10 | Alvotech resubmitted BLAs to the FDA for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar) after responding to a P | Jun 4, 2026 |
| BIIB | PRESS-RELEASE | neutral | 5/10 | Biogen and UCB presented Phase 3 PHOENYCS GO data at EULAR 2026 for dapirolizumab pegol (DZP) in systemic lupus erythema | Jun 4, 2026 |
| JBIO | PRESS-RELEASE | bearish | 6/10 | Jade Biosciences priced a public offering of 10 million shares at $15.00 per share, expecting gross proceeds of $150 mil | Jun 3, 2026 |
| JBIO | PRESS-RELEASE | bearish | 6/10 | Jade Biosciences announced an underwritten public offering of common stock and pre-funded warrants, with a 30-day underw | Jun 3, 2026 |
| MAIA | PRESS-RELEASE | bullish | 6/10 | MAIA Biotechnology announced FDA clearance of an IND amendment to open U.S. enrollment for the expansion of its Phase 2 | Jun 3, 2026 |
| INAB | PRESS-RELEASE | neutral | 3/10 | IN8bio announced the publication of a review article in Nature Communications co-authored by its CSO, highlighting advan | Jun 3, 2026 |
| NRXP | PRESS-RELEASE | bearish | 6/10 | NRx Pharmaceuticals priced an underwritten public offering of 5,714,286 shares at $3.50/share, with gross proceeds of ~$ | Jun 3, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber published an inaugural corporate investor presentation consolidating previously announced milestones: LOIs | Jun 3, 2026 |
| TGTX | PRESS-RELEASE | bullish | 7/10 | TG Therapeutics announced positive Phase 1 data for a subcutaneous formulation of BRIUMVI, showing favorable pharmacokin | Jun 3, 2026 |
| DYN | PRESS-RELEASE | neutral | 5/10 | Dyne Therapeutics announced completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE tri | Jun 3, 2026 |
| KURA | PRESS-RELEASE | bullish | 7/10 | Kura Oncology presented Phase 1a data at ASCO 2026 showing darlifarnib + adagrasib achieved confirmed objective response | Jun 3, 2026 |
| CATX | PRESS-RELEASE | neutral | 5/10 | Perspective Therapeutics announced the first patient dosed with [212Pb]VMT-α-NET in a new meningioma cohort of its ongoi | Jun 3, 2026 |